Drug Profile
CF 1743
Alternative Names: CF-1743Latest Information Update: 14 Jul 2009
Price :
$50
*
At a glance
- Originator Rega Institute for Medical Research; University of Wales
- Developer FermaVir Pharmaceuticals
- Class Antivirals; Nucleosides; Pyrimidines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Herpes zoster
Most Recent Events
- 14 Jul 2009 Discontinued - Preclinical for Herpes zoster in USA (Topical)
- 20 Sep 2007 FermaVir Pharmaceuticals has been acquired by Inhibitex
- 20 Sep 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2007) added to the Viral Infections antimicrobial activity section